Back to Search
Start Over
Trained Immunity-Based Vaccine in B Cell Hematological Malignancies With Recurrent Infections: A New Therapeutic Approach
- Source :
- Frontiers in Immunology, Vol 11 (2021), Frontiers in Immunology
- Publication Year :
- 2021
- Publisher :
- Frontiers Media S.A., 2021.
-
Abstract
- Infectious complications are a major cause of morbidity and mortality in B-cell hematological malignancies (HM). Prophylaxis for recurrent infections in HM patients with antibody deficiency consists of first-line antibiotics and when unsuccessful, gammaglobulin replacement therapy (IgRT). Recent knowledge of trained immunity-based vaccines (TIbV), such as the sublingual polybacterial formulation MV130, has shown a promising strategy in the management of patients with recurrent infections. We sought to determine the clinical benefit of MV130 in a cohort of HM patients with recurrent respiratory tract infections (RRTIs) who underwent immunization with MV130 for 3 months. Clinical information included the frequency of infections, antibiotic use, number of visits to the GP and hospitalizations previous and after MV130 immunotherapy. Improvement on infection rate was classified as: clear (>60% reduction of infection), partial (26%–60%) and low (≤25%) improvement. Fifteen HM patients (aged 42 to 80 years; nine females) were included in the study. All patients reduced their infection rate. Analysis of paired data revealed that the median (range, min - max) of respiratory infectious rate significantly decreased from 4.0 (8.0–3.0) to 2.0 (4.0–0.0) (pp = 0.002) during 12 months after initiation of treatment with MV130. The number of infectious-related GP or emergency room visits declined from 4.0 (8.0–2.0) to 2.0 (3.0–0.0) (pp = 0.032). Regarding safety, no adverse events were observed. On the other hand, immunological assessment of serum IgA and IgG levels demonstrated an increase in specific antibodies to MV130-contained bacteria following MV130 immunotherapy. In conclusion, MV130 may add clinical benefit reducing the rate of infections and enhancing humoral immune responses in these vulnerable patients.
- Subjects :
- Adult
Male
lcsh:Immunologic diseases. Allergy
medicine.medical_specialty
Time Factors
medicine.drug_class
medicine.medical_treatment
Immunology
Antibiotics
Pilot Projects
recurrent respiratory tract infections
MV130
Immune system
Immunity
Internal medicine
medicine
Humans
Immunology and Allergy
Vaccines, Combined
hematological malignancies
Respiratory system
Adverse effect
Respiratory Tract Infections
Original Research
Aged
Retrospective Studies
Aged, 80 and over
trained immunity-based vaccines
Antigens, Bacterial
business.industry
Immunotherapy
Middle Aged
Antibodies, Bacterial
Anti-Bacterial Agents
Immunity, Humoral
Immunoglobulin A
Treatment Outcome
Immunoglobulin M
Immunization
Hematologic Neoplasms
Reinfection
Bacterial Vaccines
Cohort
Female
prophylaxis
business
lcsh:RC581-607
IgA
Subjects
Details
- Language :
- English
- ISSN :
- 16643224
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- Frontiers in Immunology
- Accession number :
- edsair.doi.dedup.....baee3f801212f461f76f8013f7d82e87